Iron Status in Prospective Blood Donors

Nielsen, Peter; Benn, Howard; Peters, Claudia; Fischer, Richard; Darda, C.; Knoedler, Bryan; Gabbe, E. E.; Kuehnl, P.

doi:10.1159/000223219

Cited by 5 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This is in perfect agreement with a screening study in 2812 prospective blood donors from Hamburg, in which increased values of serum iron and/or serum ferritin were used as filter parameters. A relevant iron overload was found in seven subjects, giving a prevalence of 1:402 ( Nielsen et al , 1995 ).…”

Section: Discussionmentioning

confidence: 97%

Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany

et al. 1998

View full text Add to dashboard Cite

Summary. Mutation analysis was performed for two HFE mutations (C282Y, H63D) in unrelated patients with hereditary haemochromatosis (n ¼ 92), family members of patients (n ¼ 34), and unrelated controls (n ¼ 157) from Northern Germany. 87/92 patients (94·6%) revealed the C282Y mutation in homozygous form, five were heterozygous. No H63D mutation was found in 174 chromosomes of patients homozygous for C282Y, whereas four of the heterozygote patients also carried the H63D mutation. Among the control group, 9·6% were heterozygotes for C282Y. 2/157 subjects were homozygous, 37/157 were heterozygous for the H63D mutation, but showed no signs of iron overload.

show abstract

Section: Discussionmentioning

confidence: 97%

Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany

et al. 1998

View full text Add to dashboard Cite

show abstract

“…This is indicated by the fact that the number of patients with severe clinical symptoms in more recent studies is much lower than in older ones (table 2), also demonstrating the progress in early diagnosis of haemochromatosis in the last years. On the other hand, screening studies in healthy populations [40,41], for example in blood donors, may theoretically exclude sick persons and therefore tend more to underestimate the number of clinically affected haemochromatosis patients. The actual view on the penetrance of the disease is that the morbidity of haemochromatosis can only be low because two large studies in unselected populations have found only a very low number (about 1%) of clinically affected subjects [42,43].…”

Section: Clinical Symptomsmentioning

confidence: 99%

“…An even higher number of subjects will be detected who are homozgous for C282Y but who are at the time of diagnosis not affected in a clinical sense. These subjects would represent a group of optimal blood donors [41]. On the other side, it should also be noted that questions about the penetrance of clinical expression, the efficacy of early treatment and the screening accuracy are yet not finally answered [65].…”

Section: Population-based Screening For Haemochromatosis: Yes or No?mentioning

confidence: 99%

Diagnosis of Hereditary Haemochromatosis using Non-Invasive Methods

Nielsen¹,

Fischer²,

Engelhardt³

et al. 2003

Transfus Med Hemother

Self Cite

View full text Add to dashboard Cite

Hereditary (idiopathic, genetic) haemochromatosis is a genetic disease in which food iron absorption is inadequately increased and not balanced to the body iron stores. As a consequence, untreated patients have a risk to develop iron overload which can give rise to various iron-induced organ damages, leading in some cases to multi-organ dysfunction (liver cirrhosis, diabetes, cardiomyopathy). Diagnosis in this iron loading disease was formerly based on highly increased transferrin saturations, elevated serum ferritin concentrations and on excessive iron deposits in biopsy material from liver. After the identification of the HFE gene and its most common mutations, a genetic diagnosis independent from iron stores has become available. Because of individual variations in the loading process, diagnostic criteria are still necessary to characterise the risks of a given patient to develop iron-induced lesions and clinical symptoms. This review describes the current knowledge of the molecular pathology and discusses criteria for diagnosis and screening of hereditary haemochromatosis. Non-invasive liver iron quantification could represent the optimal complement to the HFE gene testing. Data on our experience with SQUID biosusceptometry, which makes liver biopsy unnecessary in most cases, are presented.

show abstract

“…Allerdings sind die Angaben zu Prävalenzen für Eisenmangel und Eisenmangelanämie sehr heterogen und beruhen teilweise auf Erhebungen aus den 90er-Jahren. So kam eine Untersuchung bei Erstblutspendern aus dem Jahr 1995 zu dem Ergebnis, dass bei 43 % der Frauen und 6 % der Männer ein Eisenmangel vorlag [10]. Hochgerechnet entspricht dies ca.…”

unclassified

Kosten-Kosten-Studie zur parenteralen Eisentherapie bei Eisenmangelanämie in der ambulanten Versorgung der GKV in Deutschland

Bierbaum¹,

Schöffski²

2013

Gesundh ökon Qual manag

View full text Add to dashboard Cite

Zusammenfassung Zielsetzung: Im Rahmen der vorliegenden Arbeit wird die Wirtschaftlichkeit parenteraler Eisenpr?parate in der ambulanten Versorgung aus der Perspektive der GKV untersucht. Methodik: Als Ausgangspunkt der Untersuchung dienten die Abrechnungsdaten der Apothekenrechenzentren. F?r die weiteren Berechnungen wurden die Vorgaben der jeweiligen Fachinformationen zugrunde gelegt. Als Kostenkomponenten wurden Arzneimittel, Verbrauchsmaterialien und die Arztleistungen analysiert. Ergebnisse: Zun?chst wurde festgestellt, dass sich die Verordnungen auf zwei Pr?parate (Eisengluconat und Eisencarboxymaltose) konzentrieren. Ebenfalls sind nur 2 Arztgruppen relevant, es dominieren die Allgemeinmediziner/Praktiker/haus?rztlich t?tigen Internisten (API) und die Nephrologen. Zwischen den verordneten Eisenmengen wurden in Abh?ngigkeit von Medikament und Arztgruppe erhebliche Unterschiede deutlich. Auch die betrachteten Kostenkomponenten zeigten eine hohe Bandbreite mit starkem Einfluss auf die ?konomische Vorteilhaftigkeit der betrachteten Pr?parate. Schlussfolgerung: Das Behandlungsgeschehen konzentriert sich auf lediglich 2 Pr?parate, deren ?konomische Vorteilhaftigkeit aus Sicht der GKV neben den reinen Arzneimittelkosten stark von den weiteren Kostenkomponenten abh?ngt. Es kann gezeigt werden, dass ein reiner Preisvergleich der Alternativen nicht ausreicht, um eine patientenorientierte und effiziente Versorgung sicherzustellen.

show abstract

Iron Status in Prospective Blood Donors

Cited by 5 publications

References 0 publications

Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany

Prevalence of the C282Y and H63D mutations in the HFE gene in patients with hereditary haemochromatosis and in control subjects from Northern Germany

Diagnosis of Hereditary Haemochromatosis using Non-Invasive Methods

Kosten-Kosten-Studie zur parenteralen Eisentherapie bei Eisenmangelanämie in der ambulanten Versorgung der GKV in Deutschland

Contact Info

Product

Resources

About